Meridian Bioscience, Inc. (VIVO)
| Market Cap | 978.89M |
| Revenue (ttm) | 253.67M |
| Net Income (ttm) | 46.19M |
| Shares Out | 42.86M |
| EPS (ttm) | 1.07 |
| PE Ratio | 21.35 |
| Forward PE | 17.15 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $22.84 |
| Previous Close | $21.59 |
| Change ($) | 1.25 |
| Change (%) | 5.79% |
| Day's Open | 22.40 |
| Day's Range | 22.12 - 23.00 |
| Day's Volume | 423,421 |
| 52-Week Range | 5.57 - 26.41 |
Meridian Bioscience (VIVO) closed at $22.13 in the latest trading session, marking a +1.33% move from the prior day.
CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fis...
Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and curr...
Low-beta stocks may be able to help sail through the choppy market conditions.
Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicine...
We have narrowed down our search to five small cap stocks that have strong growth potential for 2021. These are: SCHL, SCHN, RYI, PTSI, VIVO.
Investors always look for companies with a high level of profitability regardless of the ongoing market condition.
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participat...
Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is (VIVO) Outperforming Other Medical Stocks This Year?
Here are six best-performing stocks with substantial net profit margins that can contribute toward making an enriching portfolio.
In my opinion, investors may want to consider the three stocks that are listed in this article, since they could meet the following value criteria:
CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has b...
Let's take a look at these six top-ranked stocks with impressive net profit margins for a winning portfolio.
Is (VIVO) Outperforming Other Medical Stocks This Year?
CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has s...
Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced toda...
CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Ke...
To combat the choppy market conditions, it is of utmost importance to create a portfolio of low-beta stocks.
Is (VIVO) Outperforming Other Medical Stocks This Year?
CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President a...
Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2020 Results - Earnings Call Transcript
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 35.71% and 7.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter an...
Despite the huge market rally since March, there are still some great value buys among small-cap stocks, if you know where to look. The post 7 Overlooked Small-Cap Stocks To Buy For Growth app...
CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that ...
CINCINNATI, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is please...
CINCINNATI, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President...
Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q3 2020 Results - Earnings Call Transcript
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 129.17% and 28.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...
CINCINNATI, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020.
Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.
Meridian Bioscience (VIVO) closed at $24.49 in the latest trading session, marking a -1.84% move from the prior day.
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.
CINCINNATI, July 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2...
CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today tha...
Is (VIVO) Outperforming Other Medical Stocks This Year?
Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Meridian Bioscience has thrived during the COVID-19 pandemic. Can this stock go much higher, or is it time to cash out?
This selection of growth stocks includes some surprise choices and companies set to benefit from the lasting effects of the pandemic.
Meridian Bioscience (VIVO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CINCINNATI, May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that...
About VIVO
Meridian Bioscience, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoas... [Read more...]
| Industry Diagnostics & Research | |
| CEO John Kenny | Employees 750 |
| Stock Exchange NASDAQ | Ticker Symbol VIVO |
Financial Performance
In 2020, VIVO's revenue was $253.67 million, an increase of 26.19% compared to the previous year's $201.01 million. Earnings were $46.19 million, an increase of 89.43%.
Analyst Forecasts
According to 4 analysts, the average rating for VIVO stock is "Buy." The 12-month stock price forecast is 26.67, which is an increase of 16.77% from the latest price.